Jazz Pharmaceuticals plc (NASDAQ:JAZZ) SVP Mary Elizabeth Henderson Sells 1,410 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) SVP Mary Elizabeth Henderson sold 1,410 shares of the firm's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Stock Down 1.8 %

Shares of Jazz Pharmaceuticals stock traded down $1.97 on Wednesday, hitting $105.13. The company had a trading volume of 463,899 shares, compared to its average volume of 689,045. The stock has a 50-day moving average of $109.79 and a 200-day moving average of $111.79. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $137.38. The firm has a market capitalization of $6.63 billion, a P/E ratio of 21.79, a P/E/G ratio of 1.34 and a beta of 0.57.

Analyst Ratings Changes

Several equities analysts recently weighed in on JAZZ shares. Piper Sandler cut their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating on the stock in a report on Thursday, August 1st. JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a research note on Monday, August 19th. Wells Fargo & Company decreased their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating for the company in a research note on Thursday, August 1st. Cantor Fitzgerald reissued an "overweight" rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday. Finally, Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $175.00 to $174.00 and set an "outperform" rating for the company in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $173.07.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rise Advisors LLC boosted its position in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 203 shares during the last quarter. Versant Capital Management Inc grew its position in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at $29,000. EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after buying an additional 97 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after buying an additional 116 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.